Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 17/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 16/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405144 | 0.95 | TLR7 (0.90) | TLR7TLR9SMN1; SMN2EHMT2EHMT1 | |
| SCHEMBL19405146 | 0.91 | TLR7 (0.83) | TLR7TLR9SMN1; SMN2EHMT2EHMT1 | |
| SCHEMBL19405147 | 0.91 | TLR7 (0.83) | TLR7TLR9SMN1; SMN2EHMT2EHMT1 | |
| SCHEMBL29936965 | 0.90 | TLR7 (0.82) | TLR7TLR9SMN1; SMN2EHMT2EHMT1 | |
| SCHEMBL19405218 | 0.90 | TLR7 (0.82) | TLR7TLR9SMN1; SMN2EHMT2EHMT1 | |
| SCHEMBL19385356 | 0.89 | TLR7 (1.00) | TLR7TLR9EHMT2EHMT1 | |
| SCHEMBL19405145 | 0.86 | TLR7 (1.00) | TLR7TLR9 | |
| SCHEMBL19405220 | 0.86 | TLR7 (0.75) | TLR7TLR9EHMT2EHMT1 | |
| SCHEMBL29936942 | 0.86 | TLR7 (0.75) | TLR7TLR9EHMT2EHMT1 | |
| SCHEMBL19385242 | 0.85 | TLR7 (1.00) | TLR7TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433249-B1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL SCIENT IND RES (IN) | 2022-11-09 | — | — | EP | claimed |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | claimed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | claimed |
| EP-3433249-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | Council Of Scientific & Industrial Research (IN) | 2019-01-30 | — | — | EP | claimed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | claimed |
| EP-3433249-B1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL SCIENT IND RES (IN) | 2022-11-09 | — | — | EP | disclosed |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | disclosed |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-05-26 | — | — | US | disclosed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | disclosed |
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-03-28 | — | — | US | disclosed |
| EP-3433249-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | Council Of Scientific & Industrial Research (IN) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017163264-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092758-A1 | BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL MOLECULE ANTAGONIST | TLR9, TLR1, TLR3 | TLR7 5/4885TLR9 1/4885SMN1; SMN2 4337/4885 |
| US-10662177-B2 | Blocking toll-like receptor 9 signaling with small molecule antagonist | TLR9, TLR1, TLR3 | TLR7 4/4885TLR9 1/4885SMN1; SMN2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.